Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals (CRVS) is a clinical-stage biopharmaceutical company advancing novel immunotherapies targeting T cell modulation through ITK inhibition. This page provides investors and industry stakeholders with timely updates on CRVS’s clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases, earnings reports, and research updates in one centralized location. Track progress across the company’s pipeline, including soquelitinib for T cell lymphomas and autoimmune conditions, as well as collaborations shaping its therapeutic platform.
Key updates include clinical trial results, partnership announcements, and financial performance. Bookmark this page to stay informed about CRVS’s advancements in immuno-oncology and immune-mediated disease research. Visit regularly for authoritative insights into the company’s scientific and operational progress.
Corvus Pharmaceuticals (NASDAQ:CRVS) announced a public offering of its common stock, with all shares being sold by the company. Underwriters may purchase an additional 15% of the shares offered. The company plans to utilize the net proceeds for its Phase 3 clinical trial of CPI-006 and other product developments. The offering is subject to market conditions, and a registration statement for these securities was filed with the SEC.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 3 clinical trial for CPI-006, targeting hospitalized COVID-19 patients. This randomized, double-blind, placebo-controlled study aims to enroll around 1,000 participants globally, with results expected in Q4 2021. Preliminary Phase 1 results showed promising outcomes, with no patients progressing to mechanical ventilation and a median hospital discharge time of 3.5 days. CPI-006 aims to stimulate B cells for enhanced antibody production, potentially addressing SARS-CoV-2 variants. A separate Phase 2 trial is planned for CPI-818 in T-cell lymphoma.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported new interim data on CPI-818 at the 62nd ASH Annual Meeting, showcasing its potential in treating T cell lymphomas and autoimmune lymphoproliferative syndrome (ALPS). The Phase 1/1b trial revealed promising anti-tumor activity, with significant tumor responses in advanced T cell malignancies. No severe treatment-related adverse events were recorded. Additionally, pre-clinical data indicated that CPI-818 could inhibit abnormal T cell activation in ALPS patients. The company plans to continue its studies and collaborate with Angel Pharmaceuticals in China.
Corvus Pharmaceuticals (CRVS) has announced new findings on its drug CPI-818 at the upcoming 62nd ASH Annual Meeting. The data includes results from a Phase 1/1b trial focused on T cell lymphoma and pre-clinical studies for treating autoimmune lymphoproliferative syndrome (ALPS). CPI-818 is an ITK inhibitor showing potential in blocking T cell activation in ALPS patients. Presentations will occur on December 5 and 6, 2020, highlighting CPI-818's efficacy and safety.
Corvus Pharmaceuticals (CRVS) announced the initiation of a pivotal Phase 2 randomized trial for CPI-006, aimed at treating COVID-19 in hospitalized patients. This trial is expected to start in December 2020, with results anticipated by mid-2021. The Phase 1 study demonstrated that CPI-006 activates a strong anti-SARS-CoV-2 antibody response and enhances patient recovery, with no reported drug-related toxicity. Key presentations highlighting the COVID-19 program will occur at the SITC Annual Meeting on November 13, 2020, showcasing CPI-006's immunotherapy potential.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the completion of patient enrollment in a Phase 1 study of CPI-006, an immunotherapy for hospitalized COVID-19 patients. Data presented at the SITC Annual Meeting indicates that CPI-006 enhances polyclonal humoral immunity, with patients showing significant antibody responses to SARS-CoV-2. Following promising results, a pivotal, randomized trial is set to begin in December 2020, with results anticipated by mid-2021. The R&D Symposium on November 12 will further detail these findings and updates on cancer programs.
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a webcast R&D Symposium on November 12, 2020, focusing on its COVID-19 program and cancer updates. The event features key presentations, including an oral presentation of CPI-006 data at the SITC Annual Meeting from November 9-14, 2020. CPI-006 showed promise in stimulating immune response in mild to moderate COVID-19 patients. The symposium will discuss ongoing clinical trials and invite questions from attendees, providing insights into Corvus's innovative approaches in immunotherapy.
Corvus Pharmaceuticals (CRVS) reported a net loss of $9.8 million for Q3 2020, improving from $11.0 million in Q3 2019. Cash reserves decreased to $51.4 million from $78.0 million at year-end 2019. R&D expenses fell to $6.6 million, while G&A expenses rose to $3.2 million. Key developments include upcoming FDA meetings for ciforadenant in renal cell cancer and promising early results for CPI-006 in COVID-19, with plans for a larger trial by year-end. The co-founding of Angel Pharmaceuticals will enhance global pipeline development.
Corvus Pharmaceuticals (NASDAQ: CRVS) is set to present updated data from its Phase 1 study of CPI-006, an immunotherapy for COVID-19, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 9-14, 2020. A poster on the study will be available during the event, highlighting CPI-006's ability to stimulate anti-SARS-CoV-2 antibody responses.
The company will also host an R&D Symposium webcast on November 12, 2020, showcasing COVID-19 program data and advancements in its cancer portfolio.
Corvus Pharmaceuticals announced a strategic collaboration with Angel Pharmaceuticals, securing a 49.7% equity stake to enhance its oncology pipeline development in China. Angel, a new biopharmaceutical company, aims to address serious diseases and launches with a $41 million financing, valuing it at $106 million. The collaboration allows for the development of three clinical-stage candidates and global BTK inhibitor programs. Clinical trials for these candidates are expected to commence within 12 to 18 months, leveraging a partnership with prominent Chinese investors and a talented local team.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
